Akero Therapeutics Investigation for Breach of Fiduciary Duties and Securities Law Violations

Berger Montague PC is investigating Akero Therapeutics and its Board of Directors for potential breaches of fiduciary duties and violations of federal securities laws related to a proposed merger with Novo Nordisk A/S. The investigation centers on the merger terms, which would give Akero shareholders $54.00 per share in cash and one Contingent Value Right entitling each holder to receive $6.00 per share if Akero's lead product candidate achieves regulatory approval by June 30, 2031. Shareholders may contact Berger Montague for more information.